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912Objective:We compared the efficacy of noninvasive ventilation with bilevel positive airway pressure added to
usual care versus usual care alone in patients undergoing coronary artery bypass grafting.
Methods:We performed a 2-group, parallel, randomized controlled trial. The primary outcome was time until
fit for discharge. Secondary outcomes were partial pressure of carbon dioxide, forced expiratory volume in 1 sec-
ond, atelectasis, adverse events, duration of intensive care stay, and actual postoperative stay.
Results: A total of 129 patients were randomly allocated to bilevel positive airway pressure (66) or usual care
(63). Three patients allocated to bilevel positive airway pressure withdrew. The median duration of bilevel
positive airway pressure was 16 hours (interquartile range, 11-19). The median duration of hospital stay until
fit for discharge was 5 days for the bilevel positive airway pressure group (interquartile range, 4-6)
and 6 days for the usual care group (interquartile range, 5-7; hazard ratio, 1.68; 95% confidence interval,
1.08-2.31; P ¼ .019). There was no significant difference in duration of intensive care, actual postoperative
stay, and mean percentage of predicted forced expiratory volume in 1 second on day 3. Mean partial pressure
of carbon dioxide was significantly reduced 1 hour after bilevel positive airway pressure application, but there
was no overall difference between the groups up to 24 hours. Basal atelectasis occurred in 15 patients (24%) in
the usual care group and 2 patients (3%) in the bilevel positive airway pressure group. Overall, 30% of patients
in the bilevel positive airway pressure group experienced an adverse event compared with 59% in the usual
care group.
Conclusions: Among patients undergoing elective coronary artery bypass grafting, the use of bilevel positive
airway pressure at extubation reduced the recovery time. Supported by trained staff, more than 75% of all
patients allocated to bilevel positive airway pressure tolerated it for more than 10 hours. (J Thorac Cardiovasc
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The long-term benefits of coronary artery bypass grafting
(CABG) for patients withmultivessel coronary heart disease
are established but must be weighed against possible short-
term iatrogenic harm. CABG interferes with pulmonary
function, with basal atelectasis detected in up to 94% of pa-
tients in the first 48 postoperative hours.1,2 Basal atelectasis
is associated with decreased lung compliance, a higher
incidence of infection, and prolonged hospital stay.2,3
Postoperative physiotherapy, often incorporating incen-
tive spirometry, is now usual care after CABG. The term
‘‘enhanced recovery’’ comprises various evidence-based
components of perioperative care and aims to expedite
recovery after surgery. In recent years, the concept of
enhanced recovery4 has become more accepted. There is
interest in the role of noninvasive ventilation (NIV) after
cardiac surgery given the benefits of NIV in respiratory
failure in other clinical settings, for example, exacerbationsery c October 2013
Abbreviations and Acronyms
BLPAP ¼ bilevel positive airway pressure
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CICU ¼ cardiac intensive care unit
CPAP ¼ continuous positive airway pressure
FEV1 ¼ forced expiratory volume in 1 second
FFD ¼ fit for discharge
ICU ¼ intensive care unit
IQR ¼ interquartile range
NIPSV ¼ noninvasive pressure support ventilation
NIV ¼ noninvasive ventilation
PaCO2 ¼ partial pressure of carbon dioxide
PPT ¼ postoperative physical therapy
SD ¼ standard deviation
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Mof chronic obstructive pulmonary disease,5 cardiogenic
pulmonary edema, and pneumonia.
There is some evidence that NIV after extubation may
be beneficial. For example, preventive use of continuous
positive airway pressure (CPAP) or bilevel positive airway
pressure (BLPAP) can reduce postoperative lung restriction
and venous admixture.6 BLPAP developed from CPAP in
the 1990s. It matches the respiratory cycle by generating
2 different positive airway pressure levels.7 BLPAP can
improve gas exchange and oxygenation,8-10 even in the
absence of hypercapnea, and BLPAP was significantly
more effective than CPAP in treating postoperative
atelectasis after CABG in a randomized comparison in
150 patients.11 Another recent trial of BLPAP after
CABG showed reductions in atelectasis but not in other
clinical measurements.12 However, these trials did not
optimize BLPAP. It has been suggested that intermittent
postoperative NIV for up to 3 hours should be part of
standard clinical practice despite the paucity of evidence.13
There is no relevant systematic review of NIVafter cardiac
surgery. One review of incentive spirometry to prevent
postoperative pulmonary complications after CABG identi-
fied trials that confounded incentive spirometry with
co-interventions, including NIV.14
We hypothesized that BLPAP after CABG would reduce
postoperative stay by improving lung physiology and gas
exchange and reducing basal atelectasis. We conducted
a randomized controlled trial to compare BLPAP added to
usual care with usual care alone in patients undergoing
isolated first-time CABG.MATERIALS AND METHODS
Study Design
The study was a single-center, 2-group, parallel, pragmatic, randomized
controlled trial. An independent statistician generated the randomThe Journal of Thoracic and Caallocation sequence by computer in blocks (ratio 1:1). E.A.J. enrolled
and randomized participants, usually immediately before the operation,
by looking up the next numbered allocation in the sequence. Participants’
random allocations were not concealed during recruitment. The allocation
was communicated to cardiac intensive care unit (CICU) staff during the
operation so the BLPAP equipment could be prepared if required. The trial
was registered as ISRCTN85570732.
This study was approved by the Hammersmith and Queen Charlotte’s &
Chelsea research ethics committee (reference number 07/Q0406/79) on
April 9, 2007. Further approval was obtained from the research and
development department of the Imperial College Healthcare NHS Trust.
This research complies with the Helsinki Declaration.
Trial Population
The reference population was patients referred to the Hammersmith
Hospital for isolated first-time CABG using cardiopulmonary bypass
and mild hypothermia (32C). Patients requiring emergency surgery, with
a history of renal impairment (creatinine>200 mmol/L), with hepatic or
hematologic disease, with poor left ventricular function, or with chronic
infection (eg, tuberculosis, chronic bronchitis) were ineligible.
Intervention and Comparator
Immediately after surgery, all participants were mechanically ventilated
using standard method (Servo I and Servo 300; Maquet Getinge Group,
Wayne, NJ) ventilators providing a tidal volume of 7 to 10 mL/kg. Immedi-
ately after weaning and extubation, participants received BLPAP treatment
in addition to usual care (BLPAP group) or usual care alone, as allocated.
We aimed to maximize the duration of BLPAP during the first 24 hours
after extubation. BLPAP was administered through an oronasal mask,
which was worn continuously except when a participant needed to eat or
drink. BLPAP was discontinued after 24 hours or earlier if it was not
tolerated by the participant. Inspiratory and expiratory positive airway
pressure settings were predetermined and stratified by body mass index
(BMI) (ie, 12 cm H2O and þ5 cm H2O, respectively, if BMI<30, and
17 cm H2O and 10 cm H2O if BMI 30). BLPAP was performed by
CICU staff who received training on 12 occasions before the study started.
Usual care alone includedchest physiotherapy, nebulizedbronchodilators
(2.5 mg salbutamol every 6 hours), coughing exercises, nebulized saline
(5 mL every 6 hours), mobilization, and incentive spirometry, overseen by
physiotherapists twice per day for the first 2 to 3 days after surgery.
Outcomes
The primary outcome was days until fit for discharge (FFD), measured
from the operation date. A judgment of FFD required (1) normal blood pres-
sure, heart rate, temperature, andoxygen saturationonair; (2) bowels open; (3)
back to preoperativemobility/reasonablemobility; and (4) satisfactorywound
healing. FFD was chosen to reflect the overall speed of recovery. It was con-
sidered an important measure for patients, clinicians, and health services that
would be unaffected by nonmedical factors. FFD and serious complications
(postoperative morbid events considered to lengthen expected hospital stay)
were judged by the clinical team, who were not blinded to allocation.
Secondary outcomes included arterial partial pressure of carbon dioxide
(PaCO2) and forced expiratory volume in 1 second (FEV1), atelectasis
scored clinically and radiologically, complications, intensive care unit
(ICU) length of stay, and time until actual discharge. PaCO2 was measured
immediately after extubation and at 1, 12, and 24 hours later. FEV1 was
measured on days 1, 2, and 3 after surgery. However, because of sternotomy
wound pain, acceptable measurements (European Respiratory Society
criteria) were achieved in only a minority of patients.15
Atelectasis was assessed on day 1 after surgery by the senior clinical
team, not involved in the trial but responsible for the patients’ care, as
present or absent on the basis of standard clinical and chest x-ray criteria.
Radiologists reporting on x-rays were blinded to allocation.rdiovascular Surgery c Volume 146, Number 4 913
FIGURE 1. Patient flow in the trial. *All received conventional manage-
ment. For 6 patients requiring noninvasive ventilation support, this included
continuous positive air pressure. yAll received BLPAP but for varying dura-
tion (median time onBLPAP¼ 16 hours [interquartile range, 11-19]). zThree
participants asked to be withdrawn because they could not tolerate BLPAP
(duration of BLPAP ¼ 0 hours). BLPAP, Bilevel positive airway pressure;
NIV, noninvasive ventilation;COPD, chronic obstructive pulmonary disease.
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MPostoperative complications other than atelectasis also were recorded.
Serious complications were itemized. Other complications were recorded
as free text and classified subsequently.
Statistical Analysis
The target sample size was 126 participants. For time until FFD, the
trial had 90% power at a 5% 2-tailed significance level to detect
a standardized difference of 0.6 standard deviations (SDs) or more in log
length of stay based on geometric mean times until FFD of 10 and
8.5 days (Online Data Supplement). For PaCO2 and FEV1, we estimated
(retrospectively) that the trial had 90% power at a 5% 2-tailed significance
level to detect a standardized difference of 0.38 SD or more.
Primary analyses were by intention to treat. The analysis plan (Online
Data Supplement) specified that time until FFD, CICU stay, and actual
postoperative stay should be analyzed as time-to-event data. The analysis
of repeated PaCO2 used a mixed regression model to take into account
the repeated measurements and to adjust for PaCO2 at the time of extuba-
tion. Mean PaCO2 levels also were analyzed 1 hour after starting NIV to
test the effectiveness of administration of BLPAP. Only the day 3 FEV1
measurement was analyzed, using multivariable regression to adjust for
the baseline measurement.
Continuously scaled outcomes are described as means  SD for each
group. Treatment effects (mean differences between groups and 95%
confidence intervals [CIs]) were estimated from the regression models.
Binary/categoric outcomes are presented as frequencies. Statistical
analyses were performed using STATA version 11 (StataCorp LP, College
Station, Tex).
RESULTS
Study Population
Of 134 patients considered for the study between February
2008 and February 2011, the trial recruited 129 participants;
66 were randomly allocated to BLPAP, and 63 were ran-
domly allocated to usual care (Figure 1). Three participants
withdrew from the BLPAP group because they could not tol-
erate the mask, giving a total of 126 patients who all received
their allocatedmanagement. Six participants in the usual care
group required ventilatory support and received CPAP.
Baseline characteristics, preoperative comorbidities, opera-
tion details, and baseline respiratorymeasurements were bal-
anced (Tables 1 and 2). Two patients died; 1 in the BLPAP
group died on day 2, and 1 in the usual care group died on
day 5.
Duration of Ventilation
The median intubation time was 6 hours for both groups
(interquartile range [IQR], 5-8 and 4-10, respectively). The
median time achieved on BLPAP in the BLPAP group was
16 hours (IQR, 11-19; range, 0-22).
Primary Outcome
Time until fit for discharge. Follow-up for the 2 patients
who died in hospital was censored at the time of death.
Median times until FFD were 6 days (IQR, 5-7) and
5 days (IQR, 4-6) for the control and treatment groups,
respectively, generating a hazard ratio of 1.68 (95% CI,
1.17-2.43; P ¼ .005). Figure 2, A shows the cumulative
proportion of participants judged FFD with increasing914 The Journal of Thoracic and Cardiovascular Surgtime, with more patients in the BLPAP group than in the
usual care group judged FFD from day 3 onward.
Secondary Outcomes
Partial pressure of carbon dioxide. Mean PaCO2 levels at
1, 12, and 24 hours are shown in Table 3. PaCO2 at 1 hour
was statistically significantly different (BLPAP vs usual
care, 0.41 kPA; 95% CI, 0.73 to 0.09; P ¼ .011)
when adjusted for PaCO2 at the time of extubation, providing
evidence that BLPAP was administered efficaciously in the
study. The mean difference in PaCO2 over 24 hours (BLPAP
vs usual care) was 0.06 kPA (95% CI, 0.25 to 0.13;
P ¼ .54) when adjusted for PaCO2 at the time of extubation.
Forced expiratory volume in 1 second. Mean FEV1
levels at days 1, 2, and 3 are shown in Table 3. Absolute
values were markedly reduced in both groups postopera-
tively because of wound pain and difficulty performing
forced maneuvers. The mean difference in percent
predicted FEV1 at day 3 (BLPAP vs usual care) was 4%
(95% CI, 3 to 12; P ¼ .24) when including preoperative
percent predicted FEV1 as a covariate.
Intensive care unit length of stay. No patient died before
discharge from the ICU. Median lengths of ICU stay were
24 hours (IQR, 18-42) and 20 hours (IQR, 17-40) for the
usual care and BLPAP groups, respectively. The hazard
ratio for BLPAP versus usual care was 1.20 (95% CI,
0.84-1.71; P ¼ .306).ery c October 2013
TABLE 1. Patients’ characteristics and operation details
Patient demographics
BLPAP Usual care
Mean SD Mean SD
Age (y) 65.76 10.77 69.41 8.86
Height (cm) 169.17 7.89 168.03 7.69
Weight (kg) 81.82 18.29 80.39 14.68
BMI (kg/m2) 28.47 5.28 28.45 4.57
No. of
patients (%)
No. of
patients (%)
NYHA class
0 5 7.9 5 8
1 17 27 16 25.8
2 29 46 34 54.8
3 10 15.9 6 9.7
4 2 3.2 1 1.6
Left ventricular function
Good (>50%) 53 84.1 52 82.5
Moderate (30%-50%) 10 15.9 11 17.5
Comorbidities
Respiratory
COPD* 10 15.9 9 14.3
Smoker/ex-smoker 29 46 30 47.6
Other 3 4.8 1 1.6
Cardiovascular
Hypertension 58 92.1 54 85.7
Hypercholesterolemia 53 84.1 56 88.9
Other 4 6.4 3 4.8
Systemic
Diabetes mellitus 19 30.2 15 23.8
Other 1 1.6 1 1.6
Other
Family history 16 15.9 15 14.3
Other 1 1.6 7 11.1
None 0 0 1 1.6
Operation details Median IQR Median IQR
Bypass (min) 71 63.5-93.5 80 60-92
Crossclamp (min) 38 31-48 46 33-54
Intubation (h) 6 4-10 6 5-8
BLPAP, Bilevel positive airway pressure; SD, standard deviation; BMI, body mass
index; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary
disease; IQR, interquartile range. *Preoperative COPD was defined as FEV1%
(FEV1/FVC ratio)<70%.
TABLE 2. Baseline respiratory measurements by group
Variable
BLPAP Usual care
Mean SD Mean SD
% predicted FEV1 (L) 0.84 0.19 0.88 0.22
FVC 3.26 0.89 3.26 0.93
PaCO2 (kPA) 5.38 0.70 5.14 0.78
PaO2 29.21 13.30 33.17 13.72
Inspiratory mouth pressure* 84.28 24.08 80.81 25.82
Expiratory mouth pressure* 136.87 47.65 128.59 35.58
BLPAP, Bilevel positive airway pressure; SD, standard deviation; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity; Paco2, partial pressure
of carbon dioxide; Pao2, partial pressure of oxygen. *Inspiratory and expiratory
mouth pressure measurements were missing for approximately 33% of the patients
because they had their lung function tests performed at the referring hospital before
their admission to the Hammersmith Hospital. In this case, lung function tests were
not repeated when patients were admitted to Hammersmith Hospital.
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MTime until discharge. By censoring follow-up for the 2 pa-
tients who died, median lengths of hospital stay were 6 days
(IQR, 5-8) for both groups. The hazard ratio for BLPAP ver-
sus usual care was 1.12 (95% CI, 0.78-1.60; P ¼ .552).
Postoperative complications. Table 4 describes compli-
cations. One or more respiratory complications occurred
in 23 patients (37%) and 9 patients (14%) in the usual
care and BLPAP groups, respectively. As hypothesized,
basal atelectasis, as judged clinically, occurred less often
in the BLPAP group (2 patients, 3%) than in the usual
care group (15 patients, 24%). Nonrespiratory complica-
tions occurred with similar frequency in both groups.The Journal of Thoracic and CaDISCUSSION
There are 3 main findings of this trial. First, we success-
fully implemented BLPAP. Among participants allocated to
BLPAP, the median duration of BLPAP was 16 hours and
75%managedmore than 10 hours. Only 3 participants failed
to tolerate BLPAP. Implementation of BLPAP by the CICU
staff was accomplished with limited training. This finding
is important because continuous NIV for more than a few
hours at a time is typically considered unfeasible, and for
this reason, it is often implemented intermittently.6,13,16,17
Second, participants allocated to BLPAP were judged, on
average, to be FFD 1 day earlier than participants who had
usual care alone. Date of FFD relates strictly to postopera-
tive recovery, whereas date of actual discharge is deter-
mined by nonmedical factors (eg, social factors). This is
important to patients and health service providers because
bed availability is a limiting factor on the capacity of
cardiac surgery units in the United Kingdom.
Third, overall respiratory complications and, in particu-
lar, atelectasis occurred less often in participants allocated
to BLPAP. There were no differences between groups in
FEV1 or PaCO2 overall, but PaCO2 did differ between groups
1 hour after extubation, suggesting improved alveolar
ventilation due to BLPAP.
Study Strengths and Limitations
We believe that this is the first trial of preventive BLPAP
in addition to usual care versus usual care alone (including
incentive spirometry) after CABG. There are several
strengths of the trial. The primary outcome, time to
medically FFD,was chosen a priori as a globalmeasurement
of clinical importance. The trial was designed to be able to
detect a clinically important difference in the time until
FFD. Our findings should be applicable to publicly funded
cardiac surgery settings because the trial was carried out in
the UK NHS, there were few exclusion criteria, and the in-
tervention was implemented by the CICU staff responsible
for day-to-day care, after limited training. We wrote anrdiovascular Surgery c Volume 146, Number 4 915
FIGURE 2. A, Proportion of patients fit for discharge. B, Proportion of
patients discharged from the CICU. C, Proportion of patients discharged
from the hospital. BLPAP, Bilevel positive airway pressure; CICU, cardiac
intensive care unit.
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Manalysis plan in advance of unblinding the data to minimize
the risk of within-study selective reporting.18,19
The trial also had limitations. The randomization
sequence was not concealed. However, a high percentage
of patients were approached and consented, and the anal-
ysis of patients’ characteristics, as reported in Table 1,
shows balance between the 2 groups in patients’ demo-
graphics and comorbidities. Allocation was not con-
cealed. It was not feasible to blind the participants,916 The Journal of Thoracic and Cardiovascular Surgnurses, and research team to allocation; therefore, the pri-
mary outcome was at risk of detection bias because the
criteria for judging a patient FFD were not completely
objective. Ascertainment of complications, including
clinical assessment of atelectasis from chest x-rays
(reviewed by the cardiothoracic team on ward rounds)
and PaCO2 and FEV1 measurements, was expected to be
less at risk of bias. The frequency of atelectasis might
have been higher if computed tomography scans had
been used to make the diagnosis. Unfortunately, FEV1
measurement proved extremely difficult. Measurements
were low but consistent with postoperative FEV1 data
for patients undergoing CABG reported by other re-
searchers.20,21 Ideally, data for the 3 additional patients
randomized to the BLPAP group would have been
included (more completely reflecting the intention to
treat), but data collection was discontinued when the
participants asked to be withdrawn.
RESULTS IN THE CONTEXT OF OTHER
LITERATURE
The previous Cochrane review of incentive spirometry
(date of last search December 2004, content assessed as
up to date in April 2007) identified 4 relevant trials.14
Two trials compared postoperative physical therapy (PPT)
with PPT plus incentive spirometry.16,17 One trial
randomized patients into 3 groups, PPT plus incentive
spirometry versus PPT plus NIV using CPAP versus PPT
plus NIV with 2 levels of pressure6; this latter intervention
is similar to BLPAP but not as implemented in our trial. The
fourth trial compared PPT plus incentive spirometry versus
PPT plus CPAP NIV versus PPT plus NIV with intermittent
positive pressure breathing.22 Thus, although all of these
trials included 1 group with incentive spirometry, the com-
parator groups varied substantially. We used the same
search strategy as the Cochrane review to identify more
recent relevant literature.
In one trial, BLPAP was not started until 4 hours after
extubation and was applied for only 1 in every 3 hours.6
The authors reported the physiologic and lung function
outcomes, ICU stay, and proportion developing atelectasis
on day 2 but reported changes between preoperative and
day 1measurements, and between day 1 and day 2 measure-
ments, instead of referring both day 1 and day 2 measure-
ments to the baseline. The authors also combined CPAP
and BLPAP groups to test the effect of NIV, reporting
a statistically significant difference in the mean change in
vital capacity and FEV1 from day 1 to day 2 between the
combined groups and usual care. However, this finding
may arise from selective outcome reporting.18,19 The
difference in the frequency of postoperative atelectasis
(30% with usual care vs 15% with CPAP or BLPAP
combined, with blinded assessment) was consistent with
our own findings.ery c October 2013
TABLE 3. Partial pressure of carbon dioxide and percentage of predicted forced expiratory volume in 1 second
Paco2 (kPA)* Percentage of predicted FEV1 (L)y
Time
BLPAP Usual care
Time
BLPAP Usual care
Mean SD Mean SD Mean SD Mean SD
Post-extubation 5.19 0.69 5.35 0.84
1 h 5.10 0.85 5.58 1.09 Day 1 0.30 0.19 0.37 0.23
12 h 4.95 0.72 5.13 0.60 Day 2 0.33 0.18 0.38 0.20
24 h 4.91 0.60 4.95 0.53 Day 3 0.43 0.22 0.40 0.20
Paco2, Partial pressure of carbon dioxide; FEV1, forced expiratory volume in 1 second; BLPAP, bilevel positive airway pressure; SD, standard deviation. *Differences in mean
PaCO2 between groups were tested at 1 hour (BLPAP vs usual care,0.41 kPA; 95% CI,0.73 to0.09; P¼ .011) and across the first 24 hours (BLPAP vs usual care, 0.06 kPA;
95%CI,0.25 to 0.13; P¼ .54). yThe mean difference in percent predicted FEV1 between groups at day 3 (BLPAP vs usual care) was 4% (95%CI,3 to 12; P¼ .24), adjusted
for preoperative percent predicted FEV1.
Al Jaaly et al Perioperative ManagementAnother trial compared intermittent noninvasive pressure
support ventilation (NIPSV, a form of BLPAP, applied
4 times per day) with CPAP in 150 patients with evidence
of postoperative radiologic atelectasis.11 The patients
received CPAP or NIPSV (the maximal pressure delivered
was 30 cm H2O, positive end-expiratory pressure was
5 cm H2O, and the minimal trigger flow was selected)
4 times per day for 30 minutes. Compared with the CPAP
group, the NIPSV group had reduced atelectasis according
to a radiologic score. However, there were no statistically
significant differences in other clinical outcomes (eg, lung
function).TABLE 4. Adverse events
Adverse event
BLPAP Usual care
n % n %
Respiratory
CPAP 4 6.4 6 9.5
Reintubation 1 1.6 2 3.2
Basal atelectasis 2 3.2 15 23.8
Bibasal collapse 0 0 1 1.6
Pneumonia 0 0 2 3.2
Pleural effusion 2 3.2 0 0
Cardiovascular
Atrial fibrillation 10 15.9 7 11.1
Sinus tachycardia 0 0 1 1.6
Ventricular tachycardia 0 0 1 1.6
Cardiac arrest 1 1.6 0 0
Re-sternotomy 1 1.6 3 4.8
Ischemia 0 0 1 1.6
Neurologic
Confusion 1 1.6 2 3.17
Transient ischemic attack 0 0 1 1.6
Renal
Renal failure 4 6.4 7 11.1
Other
Liver infarct 0 0 2 3.2
Diarrhea 1 1.6 0 0
Sternal wound infection 1 1.6 1 1.6
Death 1 1.6 1 1.6
Other 0 0 1 1.6
None 44 69.8 26 41.3
BLPAP, Bilevel positive airway pressure; CPAP, continuous positive airway pressure.
The Journal of Thoracic and CaA third trial, with 4 groups (25 patients per group),
evaluated the pulmonary effects of intermittent NIV with
BLPAP (1 hour in every 6 hours), or recruitment maneuver,
compared with usual care, after open surgery.12 Although
this trial was factorial in its design, results were reported
for the 4 groups separately. All 3 intervention groups had
significantly reduced atelectasis scores (assessed blind to
allocation), with the lowest scores in the 2 BLPAP groups.
However, no differences were observed in the duration of
ICU stay or the length of hospitalization.P
MINTERPRETATION
Our finding that BLPAP reduces atelectasis is consistent
with 3 previous trials in which assessment of atelectasis was
carried out blind to treatment allocation. This finding
alone is important, because pulmonary complications and
atelectasis are associated with longer duration of hospital
stay after other types of thoracic surgery and cardiac
surgery.23-25 Patients who stay in the hospital longer than
expected reduce the availability of beds for patients
awaiting elective surgery and decrease the capacity of
cardiac surgery centers. The reduction in atelectasis with
BLPAP probably explains our finding of a reduction in
time until FFD.
Previous trials also found no significant effect of NIV
interventions similar to BLPAP for other outcome
measures, such as PaCO2 and FEV1. Our failure to observe
differences is unlikely to be explained by a lack of power
because these outcomes are measured on continuous scales,
and, in the case of PaCO2, repeated measurements were
analyzed. We also considered that these measures would
be less at risk of detection bias and, insomuch as they are
intermediary measures of improving respiratory function,
more likely to show a benefit. However, practical difficul-
ties in this pragmatic setting, with lack of absolute
standardization, for example, with respect to the fraction
of inspired oxygen during BLPAP, make them less robust.
In reconciling the findings of the primary and secondary
outcomes, one faces a choice between an explanation in
terms of bias (which could explain the difference in FFD
but not in the frequency of atelectasis) and an explanationrdiovascular Surgery c Volume 146, Number 4 917
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Min terms of the intrinsic variability of postoperative
measures of PaCO2 and FEV1. The latter were not robust
in the trial setting and are subject to large individual
differences arising from variation in patients’ pain thresh-
olds, respiratory effort in the early postoperative period,
and adherence to instructions for lung function tests.
These variations would be expected to contribute noise to
measurements of PaCO2 and FEV1.
The consistency of the findings regarding atelectasis
across 4 trials strengthens our results and provides
a mechanism for the clinical benefit we observed with
BLPAP. However, the case for implementation of routine
BLPAP after extubation in patients who have undergone
CABG cannot be considered proven, and we are exploring
the feasibility of performing a larger multicenter trial with
features to reduce the risk of bias. Given the potential re-
source implications of BLPAP reducing length of stay, it
will be important to include an economic evaluation along-
side the trial. It may also be possible to further optimize the
application of BLPAP.
CONCLUSIONS
Participants who received NIV with BLPAP in addition
to usual care were, on average, judged to be medically
FFD (study primary outcome) 1 day earlier than partici-
pants who had usual care only. If this reduction in hospital
stay could be confirmed in a larger multicenter trial, it
would represent an important benefit to patients and health
services provision, reducing the cost of an admission for
CABG and increasing the capacity of cardiac surgery units.
We conclude that BLPAP could be an important part of an
enhanced recovery program for patients undergoing CABG.
The authors thank the patients who participated and the staff in
the cardiothoracic unit who made this study possible.
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